PDS Biotechnology (NASDAQ:PDSB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

PDSB has been the topic of a number of other research reports. Weiss Ratings cut shares of PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 11th. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

Get PDS Biotechnology alerts:

Get Our Latest Stock Report on PDSB

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $0.84 on Friday. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57. The stock has a 50-day simple moving average of $0.49 and a two-hundred day simple moving average of $0.78. The firm has a market capitalization of $47.12 million, a PE ratio of -1.32 and a beta of 1.46. PDS Biotechnology has a 52-week low of $0.20 and a 52-week high of $1.55.

PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Analysts forecast that PDS Biotechnology will post -0.49 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PDSB. Bank of New York Mellon Corp bought a new stake in PDS Biotechnology in the 2nd quarter worth approximately $60,000. BlackRock Inc. purchased a new stake in shares of PDS Biotechnology during the 2nd quarter worth approximately $535,000. Finally, Renaissance Technologies LLC boosted its position in shares of PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after acquiring an additional 44,100 shares during the last quarter. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

(Get Free Report)

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.

Read More

• Five stocks we like better than PDS Biotechnology
• Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
• Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
• AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
• Insiders Signal Deep Value In DICK’s Sporting Goods

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.